Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Evogene (NASDAQ:EVGNGet Free Report) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Trading Down 3.3 %

Shares of NASDAQ EVGN opened at $0.67 on Tuesday. Evogene has a twelve month low of $0.45 and a twelve month high of $1.44. The firm has a 50-day moving average of $0.71 and a two-hundred day moving average of $0.78. The company has a market capitalization of $27.70 million, a price-to-earnings ratio of -1.46 and a beta of 1.40.

Institutional Trading of Evogene

A hedge fund recently raised its stake in Evogene stock. Silverarc Capital Management LLC increased its stake in Evogene Ltd. (NASDAQ:EVGNFree Report) by 3,000.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,100,000 shares of the biotechnology company’s stock after acquiring an additional 3,000,000 shares during the quarter. Silverarc Capital Management LLC owned approximately 7.52% of Evogene worth $1,818,000 at the end of the most recent quarter. 10.40% of the stock is owned by institutional investors and hedge funds.

Evogene Company Profile

(Get Free Report)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.

Further Reading

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.